The FDA has accepted Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the primary and solely subcutaneous, chemo-free therapy for sufferers with EGFR-mutated non-small cell lung most...
Lively Biotech has obtained optimistic suggestions from regulators on a protocol modification to its ongoing proof-of-concept scientific trial evaluating tasquinimod in sufferers with myelofibrosis, a...
When San Francisco-based surgeon Dr. Anne Peled determined to bear a sensation-preserving mastectomy following her second analysis of breast most cancers, she...
New analysis from the worldwide CATNON trial exhibits that sufferers with newly recognized 1p/19q non-co-deleted anaplastic astrocytomas who obtained radiotherapy adopted by...
